Carboplatin or Cisplatin Clinical Trials

5 actively recruiting trials across 2 locations

No change since May 2026

Also known as: chemotherapeutic drug

Pipeline

Phase 2: 4Phase 3: 1

Top Sponsors

University of Illinois at Chicago1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1
Shanghai Junshi Bioscience Co., Ltd.1
Second Hospital of Shanxi Medical University1
Hirva Mamdani1

Indications

Lung Cancer5
Cancer5
Extensive Stage-small Cell Lung Cancer2
Metastatic Squamous Non-Small Cell Lung Carcinoma1
Non-Squamous Non-Small Cell Lung Cancer1

Other3 trials

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Phase 2

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Phase 2

Chicago, Illinois1 trial

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Ryan Nguyen

Phase 2

Indianapolis, Indiana1 trial

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.